Oppenheimer Comments on Teva Pharmaceutical Industries Ltd’s Q3 2018 Earnings (TEVA)

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) – Equities researchers at Oppenheimer increased their Q3 2018 earnings estimates for Teva Pharmaceutical Industries in a research report issued on Wednesday, October 17th. Oppenheimer analyst E. Rajavelu now expects that the company will earn $0.49 per share for the quarter, up from their previous estimate of $0.47. Oppenheimer has a “Hold” rating on the stock.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Thursday, August 2nd. The company reported $0.78 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.64 by $0.14. Teva Pharmaceutical Industries had a positive return on equity of 19.92% and a negative net margin of 47.98%. The company had revenue of $4.70 billion for the quarter, compared to analysts’ expectations of $4.75 billion. During the same period in the previous year, the firm posted $1.02 earnings per share. The firm’s revenue for the quarter was down 17.8% on a year-over-year basis.

Several other equities research analysts have also recently weighed in on the company. Wells Fargo & Co set a $23.00 price objective on Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research note on Wednesday. Credit Suisse Group set a $26.00 target price on Teva Pharmaceutical Industries and gave the company a “hold” rating in a research note on Sunday, October 14th. Goldman Sachs Group raised Teva Pharmaceutical Industries from a “buy” rating to a “conviction-buy” rating and set a $30.00 target price on the stock in a research note on Monday, October 1st. Leerink Swann raised Teva Pharmaceutical Industries from an “underperform” rating to a “market perform” rating and upped their target price for the company from $16.00 to $24.00 in a research note on Monday, October 1st. Finally, Cantor Fitzgerald reaffirmed a “hold” rating and set a $25.00 target price on shares of Teva Pharmaceutical Industries in a research note on Thursday, September 27th. Five equities research analysts have rated the stock with a sell rating, sixteen have given a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $21.68.

Shares of NYSE TEVA opened at $21.43 on Friday. The company has a current ratio of 1.03, a quick ratio of 0.69 and a debt-to-equity ratio of 1.86. Teva Pharmaceutical Industries has a 1-year low of $10.85 and a 1-year high of $25.96. The company has a market cap of $21.55 billion, a price-to-earnings ratio of 5.45, a P/E/G ratio of 1.75 and a beta of 0.71.

In other news, EVP Sven Dethlefs purchased 2,000 shares of the stock in a transaction that occurred on Friday, August 3rd. The stock was purchased at an average price of $21.92 per share, for a total transaction of $43,840.00. Following the completion of the acquisition, the executive vice president now owns 6,445 shares of the company’s stock, valued at $141,274.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Deborah A. Griffin sold 2,376 shares of the business’s stock in a transaction that occurred on Tuesday, September 18th. The shares were sold at an average price of $23.71, for a total value of $56,334.96. Following the completion of the sale, the insider now owns 2,376 shares of the company’s stock, valued at approximately $56,334.96. The disclosure for this sale can be found here. Insiders sold 10,350 shares of company stock valued at $239,430 in the last quarter. 0.43% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in TEVA. Wealthstreet Investment Advisors LLC purchased a new stake in shares of Teva Pharmaceutical Industries in the second quarter valued at approximately $200,000. MAI Capital Management purchased a new stake in Teva Pharmaceutical Industries during the second quarter worth $204,000. Greenleaf Trust purchased a new stake in Teva Pharmaceutical Industries during the second quarter worth $215,000. Rehmann Capital Advisory Group lifted its holdings in Teva Pharmaceutical Industries by 136.2% during the second quarter. Rehmann Capital Advisory Group now owns 9,019 shares of the company’s stock worth $219,000 after buying an additional 5,201 shares during the period. Finally, Court Place Advisors LLC purchased a new stake in Teva Pharmaceutical Industries during the second quarter worth $220,000. Hedge funds and other institutional investors own 64.65% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Recommended Story: Hedge Funds

Earnings History and Estimates for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply